<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497900</url>
  </required_header>
  <id_info>
    <org_study_id>2006-005767-26</org_study_id>
    <nct_id>NCT00497900</nct_id>
  </id_info>
  <brief_title>The Effect of Calcium and Vitamin D in Patients With Heart Failure</brief_title>
  <acronym>KarViDII</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have shown high proportions of vitamin D deficiency among elderly in
      Denmark. Vitamin D is important for muscular function. The investigators intend to examine if
      it is possible to improve cardiovascular function in patients with heart failure and vitamin
      D deficiency by supplementation with vitamin D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is a major course of morbidity and mortality. The prevalence in the Danish
      population is 1-2% and for age 50 -75 years: 2-3% (1) . It has been estimated that there are
      currently 6.5 million HF patients in Europe and 5 million in the USA (2) . Lack of vitamin D
      has been linked to heart disease including ischemic heart disease, heart failure, and
      hypertension.(3) Vitamin D deficiency is prevalent in the elderly population. Calcium
      absorption, bone mineralization and muscle function may be impaired. Vitamin D receptors have
      also been demonstrated in skeletal as well as cardiac muscle(4) . Vitamin D and Parathyroid
      Hormone (PTH) are closely linked in the calcium metabolic system. In order to maintain serum
      calcium within range PTH and vitamin D acts together in response to changes in serum-calcium
      levels. 25(OH)D concentration also being an important factor determining the levels of
      PTH.(5) Decreasing vitamin D leads to increasing levels of PTH. Hyperparathyroidism in
      patients with kidney-disease has in numerous studies been linked to cardiovascular disease,
      left ventricle hypertrophy, and valvular calcification .(6) Aim: Intervention with vitamin D
      and calcium will improve patients' vitamin D levels and suppress PTH. Thus we hope to find an
      improved cardiac function and quality of life in the intervention-group.

      Comparison: Cardiac function (and other effect parameters - such as self-evaluated health) in
      the intervention group vs. in the placebo-group
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 minutes walk test</measure>
    <time_frame>6 months</time_frame>
    <description>combined skeletal and cardiac muscle function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Self assessed health (MLHFQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical markers</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Heart Failure</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium and vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcium and placebo (cellulose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Daily vitamin D (cholecalciferol) tablets and rocaltrol</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years of age

          -  Vitamin D (serum 25-OHD): 50nmol/l or less

          -  Heart failure (EF 40% or less, NYHA:2 or more)

        Exclusion Criteria:

          -  Calcium metabolic disturbances

          -  Granulomatous diseases

          -  Alcohol or drug abuse

          -  Intake of 400IU (or more) vitamin D/day

          -  Condition too poor to participate

          -  Pregnancy

          -  AF with HF 90 or above

          -  Mitral insufficiency, degree 3 or above

          -  Large cardiac aneurisms

          -  Significant aorta stenosis

          -  Significant aorta insufficiency

          -  Allergy to components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens-Erik B Jensen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louise Lind Schierbeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Nielsen OW, Raymond IE, Kirk V, Pedersen F, Bay-Nielsen M. [The epidemiology of heart failure from a Danish perspective]. Ugeskr Laeger. 2004 Jan 19;166(4):243-7. Review. Danish.</citation>
    <PMID>14964101</PMID>
  </reference>
  <reference>
    <citation>Holick MF. The vitamin D epidemic and its health consequences. J Nutr. 2005 Nov;135(11):2739S-48S.</citation>
    <PMID>16251641</PMID>
  </reference>
  <reference>
    <citation>O'Connell TD, Simpson RU. Immunochemical identification of the 1,25-dihydroxyvitamin D3 receptor protein in human heart. Cell Biol Int. 1996 Sep;20(9):621-4.</citation>
    <PMID>8948124</PMID>
  </reference>
  <reference>
    <citation>Pepe J, Romagnoli E, Nofroni I, Pacitti MT, De Geronimo S, Letizia C, Tonnarini G, Scarpiello A, D'Erasmo E, Minisola S. Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos Int. 2005 Jul;16(7):805-12. Epub 2004 Nov 16.</citation>
    <PMID>15551058</PMID>
  </reference>
  <reference>
    <citation>HÃ¶rl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant. 2004 Aug;19 Suppl 5:V2-8. Review.</citation>
    <PMID>15284353</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2007</study_first_submitted>
  <study_first_submitted_qc>July 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2007</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Louise Lind Schierbeck</investigator_full_name>
    <investigator_title>MD, research fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

